FDA Voices
Fifty Years of the Medical Device Amendments: Building on a Strong Foundation to Advance Safe, Effective and High-Quality Medical Devices
By: Michelle Tarver, M.D., Ph.D., Director, Center for Devices and Radiological Health
In 2026, not only is the U.S. Food and Drug Administration celebrating its 120th anniversary, but it also marks the 50th anniversary of the 1976 Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act) – a landmark moment that fundamentally shaped how medical devices are regulated in the United States. For five decades, the 1976 Amendments have served as the foundation of a regulatory framework designed to protect patients while advancing innovation. It has ultimately helped to ensure that medical devices are safe, effective, and high-quality for the people who rely on them.
The Drug Amendments of 1962 amended the FD&C Act to require that new drugs be approved by the FDA for both safety and effectiveness. After that, from 1962 to 1969, various legislative proposals were considered that would provide the FDA with strengthened regulatory authority over devices. In October 1969, President Nixon sent a message to Congress asking for minimum standards for medical devices; the Department of Health, Education, and Welfare then convened a committee to undertake a thorough study prior to supporting specific legislation. The study resulted in the Cooper Committee Report, which recommended a regulatory approach that was unique to devices and involved classification into three distinct regulatory categories. Interest in legislation was spurred on by the concerns about adverse events associated with the Dalkon Shield intrauterine device. Congress held hearings on device legislation over the course of several years and considered various legislative proposals, and eventually the Medical Device Amendments of 1976 became law.
The 1976 Amendments were enacted at a time of rapid technological advancement and growing recognition that medical devices required a tailored regulatory approach as they became more widely used, increasingly complex, and essential to patient care. Congress set out with a clear and enduring goal: to provide a reasonable assurance of the safety and effectiveness of medical devices. That goal remains at the heart of the FDA’s device regulation today.
This milestone also provides an opportunity to recognize the people behind this progress. This week, CDRH convened former leaders, alumni, and current staff whose collective experience spans decades of device oversight. Their perspectives underscore how far the field has advanced and the principles that continue to guide our work. “The innumerable successes over 50 years in the protection of patient and consumer health have depended on the regulatory authority that serves as the framework for CDRH’s continuing mission. The effectiveness of the Medical Device Amendments of 1976 in getting useless, dangerous, and fraudulent devices off the market cannot be overstated,” noted the FDA’s Archivist, Frank Riccio, at the 50th anniversary commemorative event at White Oak, MD.
A Risk-Based Framework That Endures
One of the most important contributions of the 1976 Amendments was the creation of a three-tier classification system for medical devices. By categorizing devices based on the degree of regulation necessary to provide reasonable assurance of their safety and effectiveness – Class I, II, or III – the statute established a flexible framework that accounts for patient risk.
Over time, this approach has proven both durable and adaptable. It enables the FDA to apply appropriate controls across a broad and evolving device landscape, from simple tools to complex, life-sustaining technologies. Just as importantly, it allows the regulatory system to evolve alongside scientific and technological progress, while keeping patient safety at the forefront of our decision-making.
The 1976 Amendments also established core premarket pathways that continue to be central to the FDA’s work today, the premarket approval (PMA) and the 510(k) pathways.
Together, these two pathways, plus the subsequently enacted De novo pathway, reflect the benefit-risk approach envisioned in 1976 – facilitating timely and continued access to medical devices while maintaining appropriate regulatory rigor. Over the past 50 years, the approach begun in the 1976 Amendments has helped bring tens of thousands of medical devices to market, supporting both incremental improvements and transformative innovations.
Strengthening Postmarket Oversight
The 1976 Amendments further established key postmarket authorities, reflecting the understanding that ensuring device safety does not end at market authorization. Postmarket requirements help the FDA monitor device performance in real-world use and take action when necessary to protect public health.
Over time, these authorities have been strengthened and expanded, supporting a more proactive, data-driven approach to postmarket surveillance and reinforcing the total product life cycle approach to device oversight.
A Statutory Foundation
Importantly, the 1976 Amendments did not create a static system. Instead, they established a statutory foundation that has evolved over the past 50 years through additional legislation, policy development, and scientific advancement. These updates, such as the Safe Medical Devices Act (SMDA), Mammography Quality Standards Act (MQSA), and the Food and Drug Administration Modernization Act (FDAMA), among others, have expanded the FDA’s authorities, modernized regulatory tools, and supported new approaches to evidence generation, including the use of real-world data and advances in regulatory science.
This continued evolution reflects a shared commitment across the FDA, Congress, industry, patients, providers, and other stakeholders, to ensure that the regulatory framework keeps pace with innovation while maintaining public trust.
Looking Ahead
As we reflect on 50 years of the 1976 Amendments, we are also looking ahead. The medical device ecosystem continues to evolve rapidly, with advances in digital health and artificial intelligence, diagnostics, and personalized medicine reshaping how care is delivered.
Building on the strong statutory foundation established in 1976, the FDA remains focused on advancing regulatory approaches that are agile, science-based, and patient-centered. By working collaboratively with stakeholders, investing in regulatory science, and embracing innovation in evidence generation, we can continue to support the development of safe, effective, and innovative medical devices that improve health outcomes.
At the same time, our focus remains firmly on the patients we serve. Every regulatory decision carries real-world implications for individuals, families, and communities. To underscore this impact, we are sharing a patient testimonial video that highlights how medical device innovations have made a meaningful difference in people’s lives and why our work continues to matter.
The basic structure of the 1976 Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act has served the nation well for five decades. As we mark this milestone, we both honor that legacy and look forward with a continued commitment to the principles of safety and innovation, and to the patients who remain at the center of all we do.